
Claims

1. A compound of Formula (I):



(I),

or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein

R^1 is R^{1A} and R^2 is R^{2A}, or R^1 is R^{2A} and R^2 is R^{1A},

wherein R^{1A} is -OH, $-OPO_3H_2$, $-OCH_2OPO_3H_2$, $-OC(O)R^{1A1}$, $-OC(O)OR^{1A1}$, $-OC(O)NHR^{1A1}$, $-OC(O)NR^{1A1}R^{1A2}$, or $-OR^{1A3}$,



wherein R^{1A1} and R^{1A2} are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, or $-O_{0\text{-}1}(CH_2)_mO(CH_2)_nOH$, wherein m and n are each independently 1 or 2, and

R^{1A3} is optionally substituted heteroaryl;

R^{2A} is -CHO or $-CH=NR^{2A1}$,


wherein R^{2A1} is optionally substituted heterocyclyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, $-NR^{2A1A}C(O)R^{2A1B}$, $-NR^{2A1A}S(O)_2R^{2A1B}$, $-NR^{2A1A}R^{2A1B}$, $-OR^{2A1A}$, or $-NR^{2A1A}C(NR^{2A1B})NR^{2A1C}R^{2A1D}$, and

wherein R^{2A1A}, R^{2A1B}, R^{2A1C}, and R^{2A1D} are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, or optionally substituted amino; or

R^{1A} and R^{2A} taken together with  to which they are attached form optionally substituted ;

R^3 is halo, hydrogen, optionally substituted alkyl, or optionally substituted alkoxy;

G^1 and G^2 are each independently CH or N;

L is a bond, -C(O)NH-*, -NHC(O)-*, -C(R^{4A})(R^{4B})NHC(O)-*, -C(O)-, -$S(O)_2$-, -$S(O)_2$NH-*, , -C(O)N(R^{4D})(CH_2)$_{2-3}$-*, -C(O)N(CH_3)-*, -(CH_2)OC(O)NH-*, -C(O)NHNH-*, -C(O)NHNHC(O)-*, -CH(R^{4E})NHC(O)O-*, or -C(O)NHO-*,

wherein R^{4A}, R^{4B}, R^{4D}, and R^{4E} are each independently hydrogen or optionally substituted alkyl,

R^{4C} is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, and

* represents the point of attachment to A^1; and

A^1 and A^2 are each independently optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;

provided that

when R^1 is -OH, R^3 is fluoro, L is a bond, and A^1 is optionally substituted 5-membered heteroaryl, then A^2 is not optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrazinyl, or 2,3-dihydrobenzo[b][1,4]dioxin-6-yl;

when R^1 is -CHO, R^2 is -OH, R^3 is hydrogen, and L is -C(O), then A^1 is not optionally substituted indolinyl;

when L is -C(O)NH-*, then A^1 is not optionally substituted phenyl, optionally substituted pyridinyl, or pyrimidinyl;

when R^3 is hydrogen, C_{1-4} alkyl, -CHO, or methoxy, then L is not a bond; and

the compound of Formula (I) is not 3-fluoro-5-formyl-4-hydroxy-N-(4-(pyrrolidin-1-yl)phenyl)benzenesulfonamide, 5-(4-(5-fluoropyridin-2-yl)piperazine-1-carbonyl)-2-hydroxy-3-methylbenzaldehyde, 5-(3-($1\lambda^4$,$2\lambda^2$,4-triazol-1-yl)azetidine-1-carbonyl)-2-hydroxy-3-methylbenzaldehyde, tert-butyl (3-(1-(3-formyl-4-hydroxybenzoyl)piperidin-4-yl)benzyl)carbamate, 5-(4-cyclopropyl-3-oxopiperazine-1-carbonyl)-2-hydroxy-3-methylbenzaldehyde, 2-(5-((((4-formyl-3-hydroxybenzyl)oxy)carbonyl)amino)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid, 4-formyl-3-hydroxybenzyl (6-(benzo[d]oxazol-2-yl)naphthalen-2-yl)carbamate, 5-[2-(3,4-diethoxyphenyl)-4-thiazolyl]-3-formyl-2-hydroxy-benzoic acid methyl ester, or a salt of any of the foregoing.

2. The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is -OH.

3. The compound of claim 1 or 2, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is -CHO.

4. The compound of any one of claims 1-3, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is halo.

5. The compound of any one of claims 1-3, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is fluoro.

6. The compound of any one of claims 1-3, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is hydrogen.

7. The compound of any one of claims 1-3, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is methyl.

8. The compound of any one of claims 1-3, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is methoxy.

9. The compound of any one of claims 1-8, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G^1 and G^2 are both CH.

10. The compound of any one of claims 1-8, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G^1 is CH and G^2 is N.

11. The compound of any one of claims 1-10, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is a bond.

12. The compound of any one of claims 1-10, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -C(O)NH-*.

13. The compound of any one of claims 1-10, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -NHC(O)-*.




14. The compound of any one of claims 1-10, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -C(O)-.




15. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is optionally substituted aryl.

16. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is optionally substituted cycloalkyl.

17. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is optionally substituted heteroaryl.

18. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is optionally substituted heterocyclyl.

19. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is , , ,




, or , wherein ** represents the point of attachment to A^2.

20. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, phenyl, pyridinyl, pyridazinyl, azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted.

21. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is optionally substituted thiazolyl.

22. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is optionally substituted thiadiazolyl.

23. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is optionally substituted pyrazolyl.








24. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^1 is optionally substituted piperidinyl.


25. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is optionally substituted aryl.

26. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is optionally substituted cycloalkyl.

27. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is optionally substituted heteroaryl.

28. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is optionally substituted heterocyclyl.

29. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is , , , , , , , , .






30. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is pyrrolidinyl, piperidinyl, piperazinyl, phenyl, pyridinyl, pyridazinyl, pyrimidinyl, or pyrazinyl, each of which is optionally substituted.


31. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is optionally substituted phenyl.


32. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is optionally substituted piperidinyl.


33. The compound of any one of claims 1-24, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A^2 is optionally substituted pyridinyl.


34. The compound of any one of claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein  is ,





































































,

,

,






,

,

,

,

, or

.


35. The compound of any one of claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein  is ,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



, 
, 
, 
, 
, 
, 
, or 
.


36. The compound of any one of claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein  is ,

, 
, 
, or 
.


37. The compound of any one of claims 1-36, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the  portion of the compound is 
, 
, 
,

















































































































, or

.









38. The compound of any one of claims 1-36, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the  portion of the compound is , , , or .









39. A compound ~~of Table 1~~, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is selected from the group consisting of~~.~~









Compound No.	Chemical Structure
1	
2	
3	
4	
5	
6	
7	
8	







9	
10	
11	
12	
13	
14	
15	
16	
17	






18	
19	
20	
21	
22	
23	
24	
25	
26	






27	
28	
29	
30	
31	
32	
33	
34	







35	
36	
37	
38	
39	
40	
41	
42	









43	
44	
45	
46	
47	
48	
49	
50	










51	
52	
53	
54	
55	
56	










57	
58	
59	
60	
61	








62	
63	
64	
65	
66	









67	
68	
69	
70	
71	
72	










73	
74	
75	
76	
77	
78	
79	
80	










81	
82	
83	
84	
85	
86	
87	
88	
89	











90	
91	
92	
93	
94	
95	
96	
97	
98	








99	
100	
101	
102	
103	
104	
105	







106	
107	
108	
109	
110	
111	
112	
113	









114	
115	
116	
117	
118	
119	
120	
121	
122	







123	
124	
125	
126	
127	
128	
129	
130	
131	









132	
133	
134	
135	
136	
137	
138	
139	
140	
141	







142	
143	
144	
145	
146	
147	 racemate
148	 *relative stereochemistry*








149	 *relative stereochemistry*
150	 *racemate*
151	 *racemate*
152	
153	
154	









155	
156	 *Relative stereochemistry*
157	 *Relative stereochemistry*
158	
159	
160	
161	
162	










163	
164	
165	
166	
167	
168	









169	
170	
171	
172	
173	
174	
175	
176	









177	
178	
179	
180	
181	
182	







183	
184	
185	
186	
187	
188	
189	

190	
191	
192	
193	
194	
195	
196	
197	


198	
199	
200	
201	
202	
203	
204	
205	
206	

207	
208	
209	
210	
211	
212	
213	
214	

215	
216	
217	
218	
219	
220	
221	
222	

223	
224	
225	
226	
227	
228	

40. A compound of Formula (I-1):



(I-1),

or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein

R^1 is R^{1A} and R^2 is R^{2A}, or R^1 is R^{2A} and R^2 is R^{1A},

wherein R^{1A} is -OH, $-OPO_3H_2$, $-OCH_2OPO_3H_2$, $-OC(O)R^{1A1}$, $-OC(O)OR^{1A1}$, $-OC(O)NHR^{1A1}$, or $-OC(O)NR^{1A1}R^{1A2}$,

wherein R^{1A1} and R^{1A2} are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, or $-O_{0\text{-}1}(CH_2)_mO(CH_2)_nOH$,

wherein m and n are each independently 1 or 2, and

R^{2A} is -CHO or $-CH=NR^{2A1}$,


wherein R^{2A1} is optionally substituted heterocyclyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, $-NR^{2A1A}C(O)R^{2A1B}$, $-NR^{2A1A}S(O)_2R^{2A1B}$, $-NR^{2A1A}R^{2A1B}$, $-OR^{2A1A}$, or $-NR^{2A1A}C(NR^{2A1B})NR^{2A1C}R^{2A1D}$, and

wherein R^{2A1A}, R^{2A1B}, R^{2A1C}, and R^{2A1D} are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroaryl;

R^3 is halo, hydrogen, optionally substituted alkyl, or optionally substituted alkoxy;

G^1 and G^2 are each independently CH or N;

L is a bond, -C(O)NH-*, -NHC(O)-*, $-C(R^{4A})(R^{4B})NHC(O)$-*, -C(O)-, $-S(O)_2$-, $-S(O)_2NH$-*,

or 

,

wherein R^{4A} and R^{4B} are each independently hydrogen or optionally substituted alkyl,

R^{4C} is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, and

* represents the point of attachment to A^1; and

A^1 and A^2 are each independently optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;

provided that




when R^1 is -OH, R^3 is fluoro, L is a bond, and A^1 is optionally substituted 5-membered heteroaryl, then A^2 is not optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrazinyl, or 2,3-dihydrobenzo[b][1,4]dioxin-6-yl;










when L is -C(O)NH-*, then A^1 is not optionally substituted phenyl, optionally substituted pyridinyl, or pyrimidinyl;










when R^3 is hydrogen, methyl, isobutyl, or methoxy, then L is not a bond; and










the compound of Formula (I) is not 3-fluoro-5-formyl-4-hydroxy-N-(4-(pyrrolidin-1-yl)phenyl)benzenesulfonamide, 5-(4-(5-fluoropyridin-2-yl)piperazine-1-carbonyl)-2-hydroxy-3-methylbenzaldehyde, 5-(3-($1\lambda^4$,$2\lambda^2$,4-triazol-1-yl)azetidine-1-carbonyl)-2-hydroxy-3-methylbenzaldehyde, tert-butyl (3-(1-(3-formyl-4-hydroxybenzoyl)piperidin-4-yl)benzyl)carbamate, or 5-(4-cyclopropyl-3-oxopiperazine-1-carbonyl)-2-hydroxy-3-methylbenzaldehyde, or a salt of any of the foregoing.









41. The compound of claim 40, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is selected from the group consisting of ~~compounds 1-139 of Table 1.~~










Compound No.	Chemical Structure
1	
2	
3	








4	
5	
6	
7	
8	
9	
10	
11	
12	






13	
14	
15	
16	
17	
18	
19	
20	
21	






22	
23	
24	
25	
26	
27	
28	
29	
30	






31	
32	
33	
34	
35	
36	
37	
38	









39	
40	
41	
42	
43	
44	
45	
46	
47	










48	
49	
50	
51	
52	
53	
54	










55	
56	
57	
58	
59	








60	
61	
62	
63	
64	








65	
66	
67	
68	
69	









70	
71	
72	
73	
74	
75	
76	
77	










78	
79	
80	
81	
82	
83	
84	
85	
86	










87	
88	
89	
90	
91	
92	
93	
94	
95	





96	
97	
98	
99	
100	
101	
102	

103	
104	
105	
106	
107	
108	
109	

110	
111	
112	
113	
114	
115	
116	
117	

118	
119	
120	
121	
122	
123	
124	
125	
126	

127	
128	
129	
130	
131	
132	
133	
134	
135	

136	
137	
138	
139	

42. A pharmaceutical composition comprising at least one compound according to any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally further comprising a pharmaceutically acceptable excipient.

~~43. A method of treating a disease or condition associated with TLR2 or TLR2 heterodimerization, comprising administering to a subject in need of such treatment an effective amount of at least one compound according to any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 42.~~

~~44. The method of claim 43, wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, fronto-temporal dementia, dementia with Lewy bodies (Lewy body disease), Parkinson's disease with dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, Progressive Supranuclear Palsy (PSP), Niemann-Pick disease type C, *Guillain–Barré syndrome* (GBS), Barrett's esophagus, inflammatory diseases, asthma, chronic obstructive pulmonary disease (COPD), chronic peptic ulcers, irritable bowel disease, tuberculosis, rheumatoid arthritis, osteoarthritis, chronic sinusitis, hepatitis, hepatitis B, hepatitis C, gout, lupus, pleurisy, eczema, gastritis, psoriasis, psoriatic arthritis, vasculitis, laryngitis, allergic reactions, multiple sclerosis, Crohn's disease, traumatic brain injury, CIDP (chronic inflammatory demyelinating polyneuropathy), stroke,~~

~~ischemic heart disease, atopic dermatitis, acne vulgaris, rosacea, non-alcoholic fatty liver disease, non-alcoholic steatohepatisis, corneal wounds, corneal disorders, corneal HSV, Stargardt disease (Juvenile macular degeneration), age-related macular degeneration, sepsis, diabetic wounds, herpes simplex virus, and anti-fungal, anti-bacterial, anitviral and antitumor diseases or conditions.~~

~~45.~~43. A compound of any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 42~~40~~, for use in the treatment of a disease or condition associated with TLR2 or TLR2 heterodimerization.

~~46.~~44. The compound of claim 43~~45~~, wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, fronto-temporal dementia, dementia with Lewy bodies (Lewy body disease), Parkinson's disease with dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, Progressive Supranuclear Palsy (PSP), Niemann-Pick disease type C, *Guillain–Barré syndrome* (GBS), Barrett's esophagus, inflammatory diseases, asthma, chronic obstructive pulmonary disease (COPD), chronic peptic ulcers, irritable bowel disease, tuberculosis, rheumatoid arthritis, osteoarthritis, chronic sinusitis, hepatitis, hepatitis B, hepatitis C, gout, lupus, pleurisy, eczema, gastritis, psoriasis, psoriatic arthritis, vasculitis, laryngitis, allergic reactions, multiple sclerosis, Crohn's disease, traumatic brain injury, CIDP (chronic inflammatory demyelinating polyneuropathy), stroke, ischemic heart disease, atopic dermatitis, acne vulgaris, rosacea, non-alcoholic fatty liver disease, non-alcoholic steatohepatisis, corneal wounds, corneal disorders, corneal HSV, Stargardt disease (Juvenile macular degeneration), age-related macular degeneration, sepsis, diabetic wounds, herpes simplex virus, and anti-fungal, anti-bacterial, anitviral and antitumor diseases or conditions.

~~47.~~45. Use of at least one compound of any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 42, in the manufacture of a medicament for the treatment of a disease or condition associated with TLR2 or TLR2 heterodimerization.

~~48.~~46. The use of claim 45~~47~~, wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, fronto-temporal dementia, dementia with Lewy bodies (Lewy body disease), Parkinson's disease with dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, Progressive Supranuclear Palsy (PSP), Niemann-Pick disease type C, *Guillain–Barré syndrome* (GBS), Barrett's esophagus, inflammatory diseases, asthma, chronic obstructive pulmonary disease (COPD), chronic peptic ulcers, irritable bowel disease, tuberculosis, rheumatoid arthritis, osteoarthritis, chronic sinusitis, hepatitis, hepatitis B, hepatitis C, gout, lupus, pleurisy, eczema, gastritis, psoriasis, psoriatic arthritis, vasculitis, laryngitis, allergic reactions, multiple sclerosis, Crohn's disease, traumatic brain injury, CIDP (chronic inflammatory demyelinating polyneuropathy), stroke, ischemic heart disease, atopic dermatitis, acne vulgaris, rosacea, non-alcoholic fatty liver disease, non-alcoholic steatohepatisis, corneal wounds, corneal disorders, corneal HSV, Stargardt disease (Juvenile macular degeneration), age-related macular degeneration, sepsis, diabetic wounds, herpes simplex virus, and anti-fungal, anti-bacterial, antiviral and antitumor diseases or conditions.

~~49.~~47. A method of interfering with the heterodimerization of TLR2 in a cell, or modulating, preventing, slowing, reversing, or inhibiting TLR2 heterodimerization in a cell, comprising contacting the cell with an effective amount of at least one compound according to any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and/or with at least one pharmaceutical composition according to claim 42, wherein the contacting is *in vitro*, or *ex vivo*~~, or *in vivo*~~.

~~50.~~48. A method of inhibiting TLR2 activation in a cell, comprising contacting the cell with an effective amount of at least one compound according to any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and/or with at least one pharmaceutical composition according to claim 42, wherein the contacting is *in vitro*, or *ex vivo*~~, or *in vivo*~~.

~~51. A method of treating a disease or condition associated with inhibition of TLR9, comprising administering to a subject in need of such treatment an effective amount of at least one compound according to any one of claims 1-41, or a tautomer thereof, or a~~

~~pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 42.~~

~~52. The method of claim 43, wherein the disease or condition is central nervous system (CNS) or peripheral disorder.~~

~~53. The method of claim 51 or claim 52, wherein the disease or condition is Parkinson's disease, Amyotrophic lateral sclerosis, Guillain-Barre syndrome, spinal cord injury, multiple sclerosis, multiple forms of tissue injury, chronic pain, or psoriasis.~~

~~54.~~49. A compound of any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 42, for use in the treatment of a disease or condition associated with inhibition of TLR9.

~~55.~~50. The compound of claim 49~~54~~, wherein the disease or condition is central nervous system (CNS) or peripheral disorder.

~~56.~~51. The compound of claim 49~~54~~ or claim 50~~55~~, wherein the disease or condition is Parkinson's disease, Amyotrophic lateral sclerosis, Guillain-Barre syndrome, spinal cord injury, multiple sclerosis, multiple forms of tissue injury, chronic pain, or psoriasis.

~~57.~~52. Use of at least one compound of any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 42, in the manufacture of a medicament for the treatment of a disease or condition associated with inhibition of TLR9.

~~58.~~53. The use of claim 52~~57~~, wherein the disease or condition is central nervous system (CNS) or peripheral disorder.

~~59.~~54. The use of claim 52~~57~~ or claim 53~~58~~, wherein the disease or condition is Parkinson's disease, Amyotrophic lateral sclerosis, Guillain-Barre syndrome, spinal cord injury, multiple sclerosis, multiple forms of tissue injury, chronic pain, or psoriasis.

~~60.~~55. A method of inhibiting TLR9 in a cell, comprising contacting the cell with an effective amount of at least one compound according to any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and/or with at least one pharmaceutical composition according to claim 42, wherein the contacting is *in vitro*, or *ex vivo*~~, or *in vivo*~~.